Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma

Normally, p53 helps prevent tumors from forming in the body. Early studies have shown that Fenofibrate, a cholesterol-lowering drug, can restore normal function to p53 and can change the metabolism of HPV-positive tumors in a way that stops the growth of tumors. The purpose of this study is to understand how Fenofibrate can be used to treat HPV-positive cervical cancers and cervical dysplasia. Researchers will examine collected tissue samples and investigate various genes and proteins to see whether Fenofibrate has an effect on HPV-positive cervical cancers and cervical dysplasia.

Trial Details

NCT ID

NCT06191133

Phase

PHASE1

Sponsor

Lindsay Ferguson, MD

Status

RECRUITING

Cancer Type

Cervical Cancer

Interventions

Fenofibrate
Cervical Conization
Hysterectomy
Chemoradiation

Locations (sample)

Cleveland, Ohio, United States|41.4995,-81.69541

Key Eligibility Criteria

Participants must have histologically or cytologic confirmed high grade dysplasia or cervical cancer. Histologic types include squamous cell, adeno…
Participants must be eligible for surgical management with LEEP, CKC or hysterectomy or chemoradiation
Age ≥ 18 years
Normal liver function (AST, ALT, bilirubin within institutional normal limits).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cervical Cancer Trials on Trialify →